<SEC-DOCUMENT>0001157523-12-000092.txt : 20120110
<SEC-HEADER>0001157523-12-000092.hdr.sgml : 20120110
<ACCEPTANCE-DATETIME>20120110111507
ACCESSION NUMBER:		0001157523-12-000092
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20120109
FILED AS OF DATE:		20120110
DATE AS OF CHANGE:		20120110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ICON PLC  /ADR/
		CENTRAL INDEX KEY:			0001060955
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-08704
		FILM NUMBER:		12519107

	BUSINESS ADDRESS:	
		STREET 1:		BANK OF NEW YORK
		STREET 2:		48 WALL ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10286
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a50124794.htm
<DESCRIPTION>ICON PLC  6-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2012 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 10pt; font-family: Times New Roman">
    <p style="text-align: center">
      <br>

    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 14pt"><b>FORM 6-K</b></font><br><br><br><font style="font-size: 12pt"><b>SECURITIES
      AND EXCHANGE COMMISSION</b></font><br><br><br><font style="font-size: 12pt">Washington,
      D.C. 20549</font><br><br><br><font style="font-family: Times New Roman; font-size: 12pt"><b>Report
      of Foreign Private Issuer</b></font><br><font style="font-family: Times New Roman; font-size: 12pt"><b>Pursuant
      to Rule 13a-16 under</b></font><br>t<font style="font-family: Times New Roman; font-size: 12pt"><b>he
      Securities Exchange Act of 1934</b></font><br><br><br>For the month ended<font style="font-family: Times New Roman; font-size: 10pt">
      January, 2012</font><br><br><br><font style="font-family: Times New Roman; font-size: 18pt"><b>ICON&#160;plc</b></font><br>(R<font style="font-family: Times New Roman; font-size: 10pt">egistrant's
      name)</font><br><br><br>0-29714<br>(Commission file number)<br><br><br>South
      County Business Park, Leopardstown, Dublin 18, Ireland<br>(Address of
      principal executive offices)<br><br>Brendan Brennan, CFO<br>South County
      Business Park Leopardstown, Dublin 18, Ireland.<br>Brendan.Brennan@iconplc.com<br>0011-353-1-291-2000<br>(Name,
      telephone number, email and/or facsmile number and address of Company
      contact person)<br><br>
    </p>
    <p>
      Indicate by check mark whether the registrant files or will file annual
      reports under cover Form 20-F or Form 40-F.<br>
    </p>
    <p style="text-align: center">
      &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes___<u><b>X</b></u>___&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No___<b>_</b>___<br><br>
    </p>
    <p>
      Indicate by check mark whether the registrant is submitting the Form 6-K
      in paper as permitted by Regulation S-T Rule 101(b)(1):<br>
    </p>
    <p style="text-align: center; white-space: nowrap">
      &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes______&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No___<u><b>X</b></u>___<br><br>
    </p>
    <p>
      Indicate by check mark whether the registrant is submitting the Form 6-K
      in paper as permitted by Regulation S-T Rule 101(b)(7):<br>
    </p>
    <p style="text-align: center; white-space: nowrap">
      &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes______&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No___<u><b>X</b></u>___<br><br>
    </p>
    <p>
      Indicate by check mark whether the registrant by furnishing the
      information contained in this Form is also thereby furnishing the
      information to the Commission pursuant to Rule 12g3-2(b) under the
      Securities Exchange Act of 1934.<br>
    </p>
    <p style="text-align: center; white-space: nowrap">
      &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes___<b>_</b>___&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No___<u><b>X</b></u>___<br><br>
    </p>
    <p style="white-space: nowrap">
      If &quot;Yes&quot; is marked, indicate below the file number assigned to the
      registrant in connection with Rule 12g3-2(b):82&#160;&#160;&#160;&#160;&#160;&#160;<b>N/A</b><br><br>
    </p>
    <div style="text-indent: 0pt; margin-bottom: 10pt; width: 100%; margin-right: 0pt; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">
      <u><font style="font-size: 10pt"><b>EXHIBIT&#160;LIST</b></font></u><br>
    </p>
<div style="text-align:left">
    <table style="font-size: 10pt; margin-bottom: 10.0px; width: 100%; font-family: Times New Roman" cellspacing="0">
      <tr>
        <td valign="top" style="text-align: left; width: 6%; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <u>Exhibit</u>
          </p>
        </td>
        <td valign="top" style="text-align: left; width: 2%; padding-left: 0.0px">
          &#160;
        </td>
        <td valign="top" style="text-align: left; width: 20%; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <u>Description</u>
          </p>
        </td>
        <td style="width: 72%">

        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 2%">

        </td>
        <td style="width: 20%">

        </td>
        <td valign="top" style="text-align: left; width: 72%; padding-left: 0.0px">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; white-space: nowrap; width: 6%; padding-right: 0.0px; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            99.1
          </p>
        </td>
        <td style="width: 2%">

        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px" colspan="2">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Icon plc Press Release dated January 9, 2012.
          </p>
        </td>
      </tr>
    </table>
    </div>
    <div style="text-indent: 0pt; margin-bottom: 10pt; width: 100%; margin-right: 0pt; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">
      <br>

    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt"><b>SIGNATURES</b></font>
    </p>
    <p>
      <font style="font-family: Times New Roman; font-size: 10pt">Pursuant to
      the requirements of the Securities Exchange Act of 1934, the registrant
      has duly caused this report to be signed on its behalf by the
      undersigned hereunto duly authorized.</font>
    </p>
<div style="text-align:left">
    <table style="font-size: 10pt; margin-bottom: 10.0px; width: 100%; font-family: Times New Roman" cellspacing="0">
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td valign="top" style="text-align: left; width: 40%; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>ICON plc</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td valign="top" style="text-align: left; width: 40%; padding-left: 0.0px">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td valign="top" style="text-align: left; width: 40%; padding-left: 0.0px">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td valign="top" style="text-align: left; width: 40%; padding-left: 0.0px">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td valign="top" style="text-align: left; width: 40%; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; width: 5%; padding-left: 0.0px">
          Date:
        </td>
        <td valign="top" style="text-align: left; width: 55%; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            January 9, 2012
          </p>
        </td>
        <td valign="top" style="text-align: left; width: 40%; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <u>/s/ Brendan Brennan</u>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td valign="top" style="text-align: left; width: 40%; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Brendan Brennan
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td valign="top" style="text-align: left; width: 40%; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Chief Financial Officer
          </p>
        </td>
      </tr>
    </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a50124794_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2012 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 8pt; font-family: Times New Roman">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 12pt"><b>ICON
      Selected by Shire plc&#8217;s Specialty Pharmaceuticals division as Global
      Strategic Partner for Clinical Research and Central Laboratory Services</b></font>
    </p>
    <p style="text-align: center">

    </p>
    <p>
      DUBLIN--(BUSINESS WIRE)--January 9, 2012--<b>ICON plc, (NASDAQ: ICLR;
      ISIN:IE0005711209), </b>a global provider of outsourced development
      services to the pharmaceutical, biotechnology and medical device
      industries, today announced that is has signed a strategic partnership
      with Shire Specialty Pharmaceuticals to serve as the sole global
      provider of central laboratory services and one of two strategic
      partners for clinical development services.
    </p>
    <p>
      As a partner for clinical development, ICON will provide Shire with a
      full range of services including site and country feasibility, ethics
      and regulatory submissions, clinical trial monitoring, project
      management, site and study team support, medical management and medical
      data review. Shire will also utilise ICON Central Laboratories&#8217;
      extensive test menu from its global network of laboratories.
    </p>
    <p>
      &#8220;We are proud that Shire Specialty Pharmaceuticals has selected ICON as
      a global partner and it is yet another endorsement of ICON&#8217;s expertise
      in operating under strategic partnership models,&#8221; commented Ciaran
      Murray, CEO, ICON plc. &#8220;ICON&#8217;s success is based on the right blend of
      development services and global testing facilities, all of which are
      underpinned by robust processes and innovative technology. We look
      forward to building on our successful relationship with Shire to help
      them realise efficiencies as they seek to bring new products to market.&#8221;
    </p>
    <p>
      <b>About ICON plc</b>
    </p>
    <p>
      ICON plc is a global provider of outsourced development services to the
      pharmaceutical, biotechnology and medical device industries. The Company
      specialises in the strategic development, management and analysis of
      programs that support clinical development - from compound selection to
      Phase I-IV clinical studies. ICON currently has around 8,500 employees,
      operating from 79 locations in 38 countries.
    </p>
    <p>
      Further information is available at <u>www.iconplc.com</u>
    </p>
    <div style="text-indent: 0pt; margin-bottom: 10pt; width: 100%; margin-right: 0pt; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">
      <i><b>Cautionary Note Regarding Forward-Looking Statements</b></i>
    </p>
    <p>
      <i>This release contains, and our officers and representatives may from
      time to time make, &quot;forward-looking statements&quot; within the meaning of
      the safe harbour provisions of the U.S. Private Securities Litigation
      Reform Act of 1995.</i> <i>Forward-looking statements can be identified
      by words such as: &quot;anticipate,&quot; &quot;intend,&quot; &quot;plan,&quot; &quot;expect,&quot; &quot;strategy&quot;
      and similar references to future periods. Forward-looking statements are
      neither historical facts nor assurances of future performance.</i> <i>Instead,
      they are based only on our current beliefs, expectations and assumptions
      regarding the future of our business, future plans and strategies,
      anticipated events and trends, the economy and other future conditions.</i>
      <i>Because forward-looking statements relate to the future, they are
      subject to inherent uncertainties, risks and changes in circumstances
      that are difficult to predict and many of which are outside of our
      control.</i> <i>Our actual results may differ materially from those
      indicated in the forward-looking statements.</i> <i>Therefore, you
      should not rely on any of these forward-looking statements. Important
      factors that could cause our actual results to differ materially from
      those indicated in the forward-looking statements include, among others,
      general economic and financial conditions; the extent to which we are
      successful in implementing our strategy, gaining new, long-term
      relationships with customers and retaining existing ones; the risk of
      competition on us and on our industry; developments and changes in laws
      and regulations; and such other factors as discussed in Part I, Item 3
      &#8220;Risk Factors&#8221; in our Form 20-F for the fiscal year ended December 31,
      2010.</i> <i>Any forward-looking statement made by us in this release is
      based only on information currently available to us and speaks only as
      of the date on which it is made.</i> <i>We undertake no obligation to
      publicly update any forward-looking statement, whether written or oral,
      that may be made from time to time, whether as a result of new
      information, future developments or otherwise.</i>
    </p>
    <p>
      ICON/ICLR-F
    </p>
    <p>
      CONTACT:<br><b>ICON Investor Contacts</b><br>Investor Relations<br>1-888-381-7923<br>or<br>Sam
      Farthing, VP Investor Relations<br>+ 353 &#8211;1-291-2251<br>or<br><b>ICON
      Media Contacts</b><br>Rosie Allan /Genevieve Tuck<br>at Weber Shandwick<br>Tel:
      +44-020-7067-0000
    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
